Trading Halt Update: Novitas Proposes Changes to LCD
MKTUPDTE
Fri, Jul 29 2022 12:16 pm
29 July 2022
TRADING HALT UPDATE: NOVITAS PROPOSES CHANGES TO LCD
DUNEDIN, New Zealand – Cancer diagnostics company Pacific Edge (NZX, ASX: PEB) became aware overnight (NZT) of the inclusion of Cxbladder CPT codes in a draft proposal for a different approach to determine which cancer biomarker tests are eligible for reimbursement by Novitas.
The publication of the proposed approach for Genetic Testing in Oncology is set out in a draft Local Coverage Determination (LCD, DL39365) and a draft Local Coverage Article (LCA, DA59125).
Pacific Edge will provide its shareholders with further clarification of the implications for Pacific Edge once it has received advice from its US legal team and other advisors prior to lifting the current trading halt.
Released for and on behalf of Pacific Edge by Grant Gibson Chief Financial Officer.
For more information:
Dr Peter Meintjes
Chief Executive
Pacific Edge
P: +64 22 032 1263
Announcement PDF
Markets News
Finance
RBNZ cuts number of jobs by 20%
The Reserve Bank claims $11m of cost savings via Project Denby’s 20% job cuts.
Primary Sector
Fonterra’s $4.2b Mainland vote set for smooth finish
It’s the second significant vote in the primary sector to be held in recent weeks.
Markets
What Nvidia and Tower Insurance have in common
One is the global stock market darling, the other is an NZX star.
